Research
Hormonal
Prebiotics (e.g., oligofructose, inulin) can improve metabolic phenotypes, reduce triglycerides, and increase satiety hormones (GLP-1, PYY) in animal models, potentially aiding weight control.
If you are considering probiotics for weight management, look for specific strains like Lactobacillus casei Shirota, L. gasseri, L. rhamnosus, or L. plantarum, as well as Bifidobacterium infantis, longum, and breve. However, do not expect all probiotics to work, as some strains have shown no effect or even increased weight gain in studies.
ModerateSupportsMEDIUM confidence
oligofructose-treated animals showed non-obese metabolic phenotypes characterized by lower triglycerides levels, adipose tissue mass, and muscle lipid infiltration.
Why this rating
Based on animal studies with varying protocols and mixed results across strains.
Source
The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity
Tomás Cerdó et al. · Nutrients · 2019
DOI 10.3390/nu11030635
narrative_reviewCited 392×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gut microbiota composition influences energy homeostasis and obesity development through mechanisms involving short-chain fatty acids (SCFAs), bile acid metabolism, and systemic inflammation.Good
- Specific probiotic strains (Lactobacillus and Bifidobacterium) can reduce body weight gain and fat accumulation in animal models of obesity, though effects are strain-specific and not universal.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →